Mesenchymal stem cells in emphysema: finding the right niche for alveolar repair

Mesenchymal stem cells in emphysema: finding the right niche for alveolar repair - Mesenchymal stem cells in emphysema

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43398

Enrollment

Registered

2016-02-11

Start date

2016-03-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

emphysema and chronic bronchitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Lung resection material will be obtained from 6-10 COPD patients and 6-10 non-COPD controls, who undergo lung transplantation or lobectomy / pneumectomy because of lung cancer. COPD patients will be selected on basis of having smoked more than 20 pack years and having clinical signs of emphysema. Written informed consent will be collected from all patients in order to be eligible for inclusion. Patients with alpha-1 antitrypsin deficiency will be excluded. The non-COPD controls will be selected on basis of having smoked less than 1 pack year and having no clinical signs of emphysema. Lung cancer patients who undergo lobectomy / pneumectomy will be selected on basis of the size and location of the tumor, enabling adequate collection of LMSCs and extracellular matrix, without interfering routine oncopathology procedures.

Exclusion criteria

Exclusion criteria: Patients with alpha-1 antitrypsin deficiency will be excluded.

Design outcomes

Primary

Measure	Time frame
•Feasibility to derive MSCs from bronchial biopsies, lung tissue resection material, and adipose tissue, •Ability of isolated MSCs to self-renew and differentiate, •Ability of isolated MSCs to expand and express growth factors, anti-inflammatory mediators, cell surface receptors and ECM proteins upon culture, •Improvement of the regenerative capacity of MSCs by the use of effector molecules, e.g. WNT proteins and IL-1R antagonists, •ECM composition of decellularized human lungs at different levels of the bronchoalveolar tree, •Engraftment, cell survival and growth factor expression of MSCs seeded on decellularized human lung slices, •Construction of 3D-scaffolds, mimicking the structure of the normal lung, using different composition of ECM molecules and growth factors, •Bio-scaffold composition that creates an optimal micro-environment that sustains MSC survival and function, •Effects of MSCs on epithelial function, e.g. epithelial barrier function, repair, mitochondrial function and differentiation into alveolosphere-like structures using Matrigel.	—

Measure

Time frame

•Feasibility to derive MSCs from bronchial biopsies, lung tissue resection material, and adipose tissue, •Ability of isolated MSCs to self-renew and differentiate, •Ability of isolated MSCs to expand and express growth factors, anti-inflammatory mediators, cell surface receptors and ECM proteins upon culture, •Improvement of the regenerative capacity of MSCs by the use of effector molecules, e.g. WNT proteins and IL-1R antagonists, •ECM composition of decellularized human lungs at different levels of the bronchoalveolar tree, •Engraftment, cell survival and growth factor expression of MSCs seeded on decellularized human lung slices, •Construction of 3D-scaffolds, mimicking the structure of the normal lung, using different composition of ECM molecules and growth factors, •Bio-scaffold composition that creates an optimal micro-environment that sustains MSC survival and function, •Effects of MSCs on epithelial function, e.g. epithelial barrier function, repair, mitochondrial function and differentiation into alveolosphere-like structures using Matrigel.

—

Secondary

Measure	Time frame
n.v.t.	—

Countries

Netherlands

Outcome results